Institutional Research Archive

Hedge Fund Letters Archive

Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.

Quarter	Letter Date	Fund Name	QTD	YTD	Tickers	Themes	Quick Take

Home Letters Funds Account

TimesSquare Capital Management U.S. FOCUS Growth Equity strategy 2024 Q1 Investor Letter | Buyside Digest

Back to Fund Profile (TimesSquare Capital Management U.S. FOCUS Growth Equity strategy)

Primary Source Intelligence • Q1 2024 Letter Analysis

TimesSquare Capital Management U.S. FOCUS Growth Equity strategy Quarterly Analysis

Buyside Digest is not affiliated with, and does not endorse, TimesSquare Capital Management U.S. FOCUS Growth Equity strategy. This analysis is provided for institutional research purposes only and is not investment advice.

Fund Returns

Annualized+23.36%

Digest Analysis

Quick Take

"TimesSquare's concentrated mid-cap growth strategy outperformed with 11.49% returns driven by technology infrastructure, healthcare utilization, and cybersecurity themes."

Executive Summary

TimesSquare's U.S. Focus Growth Strategy delivered strong first quarter performance with an 11.49% net return, outperforming the Russell Midcap Growth Index's 9.50% return. The portfolio benefited from concentrated positions in quality growth companies across technology, healthcare, and industrial sectors. Key contributors included O'Reilly Automotive (+19%) on strong professional segment growth, RenaissanceRe Holdings (+20%) with exceptional underwriting performance, and CrowdStrike (+25%) driven by cybersecurity demand. The team initiated a position in Legend Biotech following FDA approval of its multiple myeloma treatment, while exiting Synopsys due to acquisition-related concerns. Investment themes driving performance included GenAI infrastructure buildout, data center energy demands requiring grid upgrades, and healthcare utilization strength beyond GLP-1 drugs. Looking ahead, the managers expect continued technology infrastructure spending through 2024 with a shift toward data preparation applications. They maintain their bottom-up approach focused on earnings growth and business fundamentals while monitoring central bank policies and election developments.

Unlock Full Institutional Analysis

Sign in or create a free account to unlock full commentary, extracted equity pitches, and direct outbound manager source links with your 3 quarterly credits.

Sign In to Unlock (3 Free Credits)View Pricing Tiers

Institutional Meta Strategy

Meta Strategy Gauges

Algorithmic conviction, macroeconomic posture, and risk appetite signals extracted from this quarterly letter with qualitative explanations.

Signal Matrix

Market Conviction

72%

CautiousHigh

High Conviction (72%)

The strategy maintains approximately 15 concentrated positions with clear thesis explanations for each holding. Specific position sizing actions are described (initiating Legend, exiting Synopsys, trimming CrowdStrike, adding to Verisk) with detailed fundamental reasoning. The concentrated approach and active management demonstrate high-moderate conviction, though not extreme concentration.

Growth Outlook

25%

BearishBullish

Bearish (25%)

The manager expresses cautious optimism about markets with positive language around strong Q1 performance and global economic expansion, but balances this with concerns about central bank policies and election uncertainty. The outlook is constructive but measured.

Risk Appetite

40%

DefensiveAggressive

Defensive (40%)

The portfolio shows selective risk-taking with new position initiations (Legend Biotech) and active trimming of winners (CrowdStrike), while maintaining concentrated exposure to growth themes. The approach is tilted toward risk but with disciplined position management.

Capital Deployment

10%

De-riskingDeploying

De-risking (10%)

The manager shows modest net deployment activity with one new position initiation (Legend Biotech) and one full exit (Synopsys), while trimming a winner (CrowdStrike) and adding to a position on weakness (Verisk). This represents rotation and selective activity rather than significant net deployment or de-risking.

Forward Guidance

15%

CautiousExpansionary

Cautious (15%)

The manager indicates a monitoring stance for 2024, watching central banks and elections while seeking earnings growth underpinnings. The bias is slightly positive but cautious, with emphasis on fundamental analysis rather than aggressive deployment.

Language Signal

30%

BearishBullish

Bearish (30%)

Language is balanced with positive terms around strong performance, growth opportunities, and sector strength, offset by risk language around regulatory uncertainty, conservative guidance, and market monitoring. Slightly more constructive than bearish overall.

Perceived Risk

45%

Low RiskElevated

Moderate Risk (45%)

The manager acknowledges moderate risks including election-year regulatory uncertainty affecting LNG activities and central bank policy changes. Risk discussion is present but not dominant, with standard acknowledgment of market uncertainties without expressing alarm about systemic threats.

Opportunity Density

65%

ScarceAbundant

Abundant (65%)

The manager identifies multiple attractive investment themes including GenAI infrastructure, data center energy needs, grid upgrades, healthcare utilization, and cybersecurity demand. The discussion suggests a reasonably rich opportunity set across several sectors, though selectivity is emphasized.

Time Horizon

70%

Short-TermLong-Term

Decade+ (70%)

The strategy emphasizes long-term durability of growth with multi-year themes like GenAI infrastructure buildout continuing through 2024 and beyond. The manager discusses confidence in long-term growth prospects for holdings like Veeva and Legend Biotech, indicating a 2-5 year investment horizon typical of growth equity strategies.